Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

MRI-Only Simulation for Prostate MRI-Guided SBRT.

Practical radiation oncology·2026

Same author

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

The British journal of dermatology·2026

Same author

RNU4ATAC-opathy: Clinical, molecular and transcriptomic insights from a large cohort.

Genetics in medicine : official journal of the American College of Medical Genetics·2026

Same author

Linking primary care data from clinical practice research datalink to secondary care and other health-related patient data: update and implications.

International journal of population data science·2026

Same author

Cetrorelix suppresses the dominant follicle and synchronizes follicular waves and ovulation in cattle†.

Biology of reproduction·2025

Same author

Hybrid Serial Casting for Children with Idiopathic Toe Walking: Safety and Effectiveness.

Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association·2025

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Prehospital Thrombolysis: A Manual from Berlin

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Recombinant peptides in thrombolysis.

Jennifer Campbell¹, Daniel Hilleman

¹Creighton Cardiac Center, Omaha, Nebraska 68178, USA.

Seminars in Thrombosis and Hemostasis

|July 16, 2010

Summary

Recombinant thrombolytic peptides like alteplase, reteplase, and tenecteplase dissolve blood clots. These modified tissue plasminogen activators (t-PA) treat conditions such as myocardial infarction, stroke, and venous thromboembolism.

Area of Science:

Biochemistry
Pharmacology
Cardiovascular Medicine

Background:

Recombinant thrombolytic peptides, primarily modified tissue plasminogen activators (t-PA), are crucial for dissolving blood clots.
Key clinically relevant forms include alteplase, reteplase (r-PA), and tenecteplase (TNK), with r-PA and TNK engineered for enhanced half-life and fibrin specificity.
These agents are vital in managing various cardiovascular and thromboembolic diseases.

Purpose of the Study:

To review the role and applications of recombinant thrombolytic peptides in clinical practice.
To highlight the structural modifications and therapeutic advantages of r-PA and TNK over native t-PA.
To outline the established indications for thrombolytic therapy in specific disease states.

Main Methods:

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Experiment Videos

Last Updated: Jun 10, 2026

Prehospital Thrombolysis: A Manual from Berlin

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Review of existing literature on recombinant thrombolytic peptides.

Analysis of clinical applications and efficacy in ST-segment elevation myocardial infarction (STEMI), deep vein thrombosis (DVT), pulmonary embolism (PE), and ischemic stroke.

Examination of their use in peripheral arterial disease and for restoring access device function.

Main Results:

Recombinant thrombolytic peptides are essential treatments for acute ischemic events.
Thrombolytic therapy is a primary option for ischemic stroke within 3 hours of symptom onset.
It serves as an alternative for STEMI when percutaneous coronary intervention is delayed and has specific roles in DVT/PE and critical limb ischemia.

Conclusions:

Recombinant thrombolytic peptides, particularly modified t-PA variants, are indispensable in treating thromboembolic disorders.
Therapeutic strategies are tailored based on the specific condition, including stroke, myocardial infarction, and venous thromboembolism.
Ongoing research and development continue to refine these clot-dissolving agents for improved patient outcomes.